Robert Hodge is an independent consultant to the Gene Therapy and Biopharmaceutic industry focused on advancing therapies into the clinic and preparing for commercialization. Previously Vice President of Technical Development at AveXis/Novartis Gene Therapies and led the process and product development of Zolgensma from phase 2 to commercialization in the US, EU, and Japan. Prior to joining AveXis, held increasing leadership roles in manufacturing, process development, and product development at Pfizer/Hospira, Kythera Biopharmaceuticals, and Amgen